Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin‐based or irinotecan‐based therapy for colorectal cancer

Oxaliplatin (OX) and irinotecan (IRI) are used as key drugs for the first‐line treatment of metastatic colorectal cancer (mCRC). However, no biomarkers have been identified to decide which of the drugs is initially used. In this translational research (TR) of the TRICOLORE trial, the advanced colore...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer science Ročník 112; číslo 4; s. 1567 - 1578
Hlavní autoři:	Takahashi, Shin, Sakamoto, Yasuhiro, Denda, Tadamichi, Takashima, Atsuo, Komatsu, Yoshito, Nakamura, Masato, Ohori, Hisatsugu, Yamaguchi, Tatsuro, Kobayashi, Yoshimitsu, Baba, Hideo, Kotake, Masanori, Amagai, Kenji, Kondo, Hitoshi, Shimada, Ken, Sato, Atsushi, Yuki, Satoshi, Okita, Akira, Ouchi, Kota, Komine, Keigo, Watanabe, Mika, Morita, Satoshi, Ishioka, Chikashi
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England John Wiley & Sons, Inc 01.04.2021 John Wiley and Sons Inc
Témata:	aCRCS Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Biomarkers, Tumor - metabolism Cancer Cancer therapies Clinical outcomes Cloning Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - metabolism Disease-Free Survival DNA methylation Female Gene expression Genomes Humans Irinotecan Irinotecan - therapeutic use Kinases Male Metastases Middle Aged Original ORIGINAL ARTICLES Oxaliplatin Oxaliplatin - therapeutic use Paraffin Patients predictive biomarker Principal components analysis Progression-Free Survival PTEN protein Statistical analysis TRICOLORE Young Adult United States > US TRICOLORE oxaliplatin irinotecan predictive biomarker aCRCS
ISSN:	1347-9032, 1349-7006, 1349-7006
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!